748 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page. Note that if the mAb name has been updated or a duplicate mAb name exists, your specific mAb search may return a different therapeutic name. See metadata notes for details.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)
Therapeutic | Format | Highest Clinical Trial (Oct '21) | Est. Status (Oct '21) | Target | Year Proposed | 100% SI Struc. | 99% SI Struc. | 95-98% SI Struc. |
---|---|---|---|---|---|---|---|---|
abagovomab | Whole mAb | Phase-III | Discontinued | CA125 | 2006 | no | no | no |
abciximab | Fab | Approved | NFD | CD41_CD61 | 1993 | YES | no | no |
abelacimab | Whole mAb | Phase-II | Active | F11 | 2018 | no | no | YES |
abituzumab | Whole mAb | Phase-II | Active | ITGAV | 2013 | no | no | no |
abrezekimab | Fab | Phase-I | Discontinued | IL13 | 2017 | no | no | no |
abrilumab | Whole mAb | Phase-II | Discontinued | α4β7 | 2014 | no | no | no |
acapatamab | Bispecific scFv | Phase-I/II | Active | FOLH1;CD3E | 2020 | no;no | no;no | no;no |
acasunlimab | Bispecific mAb | Phase-I/II | Active | CD274;TNFRSF9 | 2020 | no;no | no;no | no;no |
acrixolimab | Whole mAb | TBC | Active | PDCD1 | 2022 | no | no | no |
actoxumab | Whole mAb | Phase-III | Discontinued | Toxin A | 2012 | no | no | no |
adalimumab | Whole mAb | Approved | Active | TNFA | 1999 | YES | YES | no |
adebrelimab | Whole mAb | Phase-III | Active | PDL1 | 2019 | no | no | no |
adintrevimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike | 2021 | no | no | no |
aducanumab | Whole mAb | Approved | NFD | APP | 2013 | YES | no | no |
afasevikumab | Whole mAb | Phase-I | Discontinued | IL17A | 2015 | YES | no | no |
alacizumab | di-Fab | Phase-II | Discontinued | KDR | 2007 | no | no | no |
alemtuzumab | Whole mAb | Approved | Active | CD52 | 2000 | YES | no | no |
alirocumab | Whole mAb | Approved | Active | PCSK9 | 2012 | no | no | no |
alnuctamab | Bispecific mAb with Domain Crossover | Phase-I | Active | TNFRSF17;CD3E | 2020 | no;no | no;no | no;no |
alomfilimab | Whole mAb | Phase-II | Active | ICOS | 2020 | YES | no | no |
alsevalimab | Whole mAb | Phase-I | Active | VTCN1 | 2019 | no | no | no |
amatuximab | Whole mAb | Phase-II | Active | MSLN | 2010 | no | YES | no |
amivantamab | Bispecific mAb | Approved | Active | EGFR;MET | 2019 | no;YES | no;no | no;no |
amlitelimab | Whole mAb | Phase-II | Active | TNFSF4 | 2020 | no | no | no |
amubarvimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | YES | YES | no |
anbenitamab | Bispecific mAb | Phase-II | Active | ERBB2 (Domain II);ERBB2 (Domain IV) | 2020 | no;YES | no;YES | no;YES |
andecaliximab | Whole mAb | Phase-III | Discontinued | MMP9 | 2016 | YES | no | no |
anetumab | Whole mAb ADC | Phase-II | Active | MSLN | 2013 | no | no | no |
anifrolumab | Whole mAb | Approved | Active | IFNAR1 | 2013 | YES | no | no |
anivovetmab | Canine Whole mAb | Unknown | Active | VP2 (Canine) | 2022 | no | no | YES |
anrukinzumab | Whole mAb | Phase-II | Discontinued | IL13 | 2007 | no | no | no |
anselamimab | Whole mAb | Phase-II | Active | SAA1 | 2021 | no | no | no |
ansuvimab | Whole mAb | Approved | Active | Zaire Ebolavirus GP1 | 2020 | no | YES | no |
anumigilimab | Whole mAb | Phase-I | Active | CSF3R | 2021 | no | no | no |
anzurstobart | Whole mAb | Phase-I | Active | SIRPα | 2022 | no | no | no |
apamistamab | Whole mAb Radiolabelled | Phase-III | Active | PTPRC | 2018 | no | no | no |
apitegromab | Whole mAb | Phase-II | Active | pro-GDF-8 | 2020 | no | no | YES |
aprutumab | Whole mAb ADC | Phase-I | Discontinued | FGFR2 | 2016 | no | no | no |
ascrinvacumab | Whole mAb | Phase-II | Active | ACVRL1 | 2015 | no | no | no |
astegolimab | Whole mAb | Phase-II | Active | IL1RL1 | 2019 | no | no | no |
atezolizumab | Whole mAb | Approved | Active | CD274 | 2014 | YES | YES | no |
atibuclimab | Whole mAb | Phase-II | Active | CD14 | 2020 | no | no | no |
atidortoxumab | Whole mAb | Phase-II | Discontinued | Toxin A | 2017 | no | no | no |
atinumab | Whole mAb | Phase-I | Discontinued | RTN4 | 2010 | no | no | no |
atoltivimab | Whole mAb | Phase-I | Discontinued | Zaire Ebolavirus GP | 2018 | no | no | no |
avdoralimab | Whole mAb | Phase-II | Active | C5AR1 | 2019 | no | no | no |
avelumab | Whole mAb | Approved | Active | CD274 | 2015 | YES | no | no |
avizakimab | Whole mAb | Phase-I/II | Active | IL21 | 2019 | no | no | no |
axatilimab | Whole mAb | Phase-II | Active | CSF1R | 2019 | no | no | no |
azintuxizumab | Whole mAb ADC | Phase-I | Discontinued | SLAMF7 | 2016 | no | no | no |
bafisontamab | Bispecific Mixed mAb and Fab | Phase-I/II | Active | EGFR;MET | 2021 | YES;no | no;no | no;no |
balstilimab | Whole mAb | Preregistration | Active | PDCD1 | 2018 | no | no | no |
bamlanivimab | Whole mAb | Approved | Active | SARS-CoV-2 Spike | 2020 | YES | no | no |
bapineuzumab | Whole mAb | Phase-II | Discontinued | APP | 2005 | no | no | YES |
bapotulimab | Whole mAb | Phase-I | Active | ILDR2 | 2020 | no | no | no |
barecetamab | Whole mAb | Phase-I | Active | ERBB3 | 2020 | YES | no | no |
barzolvolimab | Whole mAb | Phase-I | Active | KIT | 2021 | no | no | no |
basiliximab | Whole mAb | Approved | NFD | IL2RA | 1996 | YES | no | no |
batoclimab | Whole mAb | Phase-III | Active | FCGRT | 2019 | no | no | no |
bavituximab | Whole mAb | Phase-III | Active | Phosphatidylserine | 2006 | no | no | no |
bavunalimab | Bispecific Mixed mAb and scFv | Phase-I | Active | LAG3;CTLA4 | 2020 | no;no | no;no | no;no |
bebtelovimab | Whole mAb | Phase-II | Active | SARS-CoV-2 Spike RBD | 2022 | YES | no | no |
bedinvetmab | Canine Whole mAb | Approved | Active | Canine NGFB | 2018 | no | no | no |
befovacimab | Whole mAb | Phase-II | Active | TFPI | 2019 | no | no | no |
begelomab | Whole mAb | Phase-II/III | Active | DPP4 | 2014 | no | no | no |
belantamab | Whole mAb ADC | Approved | Active | TNFRSF17 | 2017 | no | no | no |
belimumab | Whole mAb | Approved | Active | TNFSF13B | 2003 | YES | no | YES |
belrestotug | Whole mAb | Phase-II | Active | TIGIT | 2022 | no | no | no |
beludavimab | Whole mAb | Phase-I/II | Active | SARS-CoV-2 Spike RBD | 2021 | no | YES | no |
bemarituzumab | Whole mAb | Phase-III | Active | FGFR2 | 2017 | no | no | YES |
benralizumab | Whole mAb | Approved | Active | IL5RA | 2009 | no | no | no |
bentracimab | Whole mAb | Phase-III | Active | AR-C124910XX | 2020 | YES | no | YES |
benufutamab | Whole mAb | Phase-I/II | Active | TNFRSF10B | 2019 | YES | no | no |
bepranemab | Whole mAb | Phase-II | Active | MAPT | 2019 | no | no | no |
berlimatoxumab | Whole mAb | Phase-II | Discontinued | Toxin A | 2017 | YES | no | no |
bermekimab | Whole mAb | Preregistration | Active | IL1A | 2018 | no | no | no |
bersanlimab | Whole mAb | Phase-II | Discontinued | ICAM1 | 2017 | no | no | no |
betifisolimab | Whole mAb | TBC | Active | CD274 | 2022 | no | no | no |
bevacizumab | Whole mAb | Approved | Active | VEGFA | 2000 | YES | no | YES |
bexmarilimab | Whole mAb | Phase-I/II | Active | STAB1 | 2019 | no | no | no |
bezlotoxumab | Whole mAb | Approved | NFD | Toxin A | 2012 | YES | no | no |
bifikafusp | Whole mAb Fusion | Phase-III | Active | FN extra domain B | 2010 | no | no | no |
bimagrumab | Whole mAb | Phase-II | Active | ACVR2B | 2012 | YES | YES | no |
bimekizumab | Whole mAb | Approved | Active | IL17A | 2013 | no | no | no |
bintrafusp | Whole mAb Fusion | Approved | Active | CD274 | 2015 | YES | no | no |
birtamimab | Whole mAb | Phase-III | Discontinued | SAA1 | 2018 | no | no | no |
bleselumab | Whole mAb | Phase-II | Discontinued | CD40 | 2015 | no | no | no |
blinatumomab | Bispecific T-Cell Engager | Approved | Active | CD19;CD3E | 2008 | no;no | no;no | no;no |
blontuvetmab | Canine Whole mAb | Unknown | Active | MS4A1 | 2015 | no | no | no |
blosozumab | Whole mAb | Phase-II | Active | SOST | 2011 | no | no | no |
bococizumab | Whole mAb | Phase-III | Discontinued | PCSK9 | 2013 | YES | no | no |
botensilimab | Whole mAb | Phase-I | Active | CTLA4 | 2020 | no | no | no |
brazikumab | Whole mAb | Phase-III | Active | IL23A | 2016 | no | no | no |
brentuximab | Whole mAb ADC | Approved | Active | TNFRSF8 | 2010 | no | no | no |
briakinumab | Whole mAb | Preregistration (w) | Discontinued | IL12B | 2009 | YES | no | no |
briquilimab | Whole mAb | TBC | Active | KIT | 2022 | no | no | no |
brodalumab | Whole mAb | Approved | Active | IL17RA | 2011 | no | no | no |
brolucizumab | scFv | Approved | Active | VEGFA | 2014 | no | no | no |
brontictuzumab | Whole mAb | Phase-I | Discontinued | NOTCH1 | 2014 | no | no | no |
budigalimab | Whole mAb | Phase-II | Active | PDCD1 | 2018 | no | no | no |
burfiralimab | Whole mAb | TBC | Active | VIM | 2022 | no | no | no |
burosumab | Whole mAb | Approved | Active | FGF23 | 2016 | no | no | no |
cabiralizumab | Whole mAb | Phase-II | Active | CSF1R | 2015 | no | no | no |
cadonilimab | Bispecific Mixed mAb and scFv | Phase-II | Active | PDCD1;CTLA4 | 2020 | no;no | no;no | no;no |
camidanlumab | Whole mAb ADC | Phase-II | Active | IL2RA | 2017 | no | no | no |
camoteskimab | Whole mAb | TBC | Active | IL18 | 2022 | no | no | no |
camrelizumab | Whole mAb | Approved | Active | PDCD1 | 2016 | no | no | no |
canakinumab | Whole mAb | Approved | Active | IL1B | 2007 | no | YES | no |
cantuzumab | Whole mAb ADC | Phase-II | Discontinued | MUC1 | 2003 | no | no | no |
caplacizumab | Nanobody | Approved | NFD | VWF | 2011 | YES | no | no |
carlumab | Whole mAb | Phase-II | Discontinued | CCL2 | 2010 | no | YES | no |
carotuximab | Whole mAb | Phase-II | Discontinued | ENG | 2015 | no | no | no |
cemiplimab | Whole mAb | Approved | Active | PDCD1 | 2018 | no | no | no |
cendakimab | Whole mAb | Phase-III | Active | IL13 | 2018 | no | no | no |
cergutuzumab | Whole mAb Fusion | Phase-I | Discontinued | CEACAM5 | 2015 | no | no | no |
certolizumab | Fab | Approved | Active | TNFA | 2004 | YES | no | no |
cetrelimab | Whole mAb | Phase-III | Active | PDCD1 | 2017 | no | no | no |
cetuximab | Whole mAb | Approved | Active | EGFR | 1999 | YES | YES | YES |
cevostamab | Bispecific mAb | Phase-I | Active | FCRL5;CD3 | 2019 | no;no | no;no | no;no |
cibisatamab | Bispecific mAb with Domain Crossover | Phase-I/II | Active | CEACAM5&CD3E;CD3E | 2017 | no;no | no;no | no;no |
cifurtilimab | Whole mAb | TBC | Active | CD40 | 2022 | no | no | no |
cilgavimab | Whole mAb | Phase-III | Active | SARS-CoV-2 Spike RBD | 2020 | YES | no | no |
cinpanemab | Whole mAb | Phase-II | Discontinued | SNCA | 2018 | YES | no | no |
cirevetmab | Canine Whole mAb | Unknown | Active | TGFB1 (Canine) | 2022 | no | no | no |
citatuzumab | Fab Fusion | Phase-I | Discontinued | EPCAM | 2008 | no | no | no |
cixutumumab | Whole mAb | Phase-II | Discontinued | IGF1R | 2008 | no | no | no |
clazakizumab | Whole mAb | Phase-III | Active | IL6 | 2012 | no | no | no |
clervonafusp | di-Fab Fusion | Phase-I/II | Active | SLC29A2 | 2018 | no | no | no |
clesrovimab | Whole mAb | Phase-III | Active | RSV gpF | 2022 | YES | no | no |
clivatuzumab | Whole mAb Radiolabelled | Phase-III | Discontinued | MUC1 | 2009 | no | no | no |
cobolimab | Whole mAb | Phase-II/III | Active | HAVCR2 | 2018 | no | no | no |
codrituzumab | Whole mAb | Phase-II | Active | GPC3 | 2013 | no | no | no |
cofetuzumab | Whole mAb ADC | Phase-I | Active | PTK7 | 2017 | no | no | no |
coltuximab | Whole mAb ADC | Phase-II | Active | CD19 | 2013 | YES | no | no |
conatumumab | Whole mAb | Phase-II | Active | TNFRSF10B | 2008 | YES | no | no |
concizumab | Whole mAb | Phase-III | Active | TFPI | 2012 | YES | no | no |
coprelotamab | Whole mAb | Phase-III | Active | ERBB2 | 2020 | YES | YES | YES |
cosfroviximab | Whole mAb | Phase-II | Active | Zaire Ebolavirus GP | 2016 | no | YES | no |
cosibelimab | Whole mAb | Phase-I/II | Active | PDL1 | 2019 | no | no | no |
crefmirlimab | scFv Engineered Dimer | Phase-II | Active | CD8A | 2022 | no | no | no |
crenezumab | Whole mAb | Phase-III | Active | APP | 2011 | YES | YES | no |
crexavibart | Whole mAb | TBC | Active | SARS-CoV-2 Spike RBD | 2022 | YES | no | no |
crizanlizumab | Whole mAb | Approved | Active | SELP | 2016 | no | no | no |
crotedumab | Whole mAb | Phase-I | Discontinued | GCGR | 2015 | no | no | no |
crovalimab | Whole mAb | Phase-III | Active | C5 | 2018 | YES | no | no |
cudarolimab | Whole mAb | Phase-I | Active | TNFRSF4 | 2019 | no | no | no |
cusatuzumab | Whole mAb | Phase-II | Active | CD70 | 2017 | no | no | no |
dacetuzumab | Whole mAb | Phase-II | Discontinued | CD40 | 2007 | no | no | no |
daclizumab | Whole mAb | Approved | Active | IL2RA | 1994 | YES | no | no |
dafsolimab | Whole mAb | Phase-III | Active | CD3E | 2020 | no | no | no |
dalotuzumab | Whole mAb | Phase-II | Discontinued | IGF1R | 2009 | no | no | no |
dalutrafusp | Whole mAb Fusion | Phase-I | Active | TGFBR2 | 2021 | no | no | no |
danburstotug | Whole mAb Fusion | Phase-II | Active | PDL1 | 2022 | no | no | no |
dapirolizumab | Fab | Phase-III | Active | CD40LG | 2013 | no | no | no |
daratumumab | Whole mAb | Approved | Active | CD38 | 2009 | YES | no | no |
datopotamab | Whole mAb | Phase-III | Active | TACSTD2 | 2019 | no | no | no |
daxdilimab | Whole mAb | Phase-II | Active | LILRA4 | 2020 | no | no | no |
dectrekumab | Whole mAb | Phase-II | Discontinued | IL13 | 2014 | no | no | no |
demcizumab | Whole mAb | Phase-I | Discontinued | DLL4 | 2012 | no | no | no |
demupitamab | Whole mAb | Phase-I | Active | EGFR | 2019 | no | YES | no |
denintuzumab | Whole mAb ADC | Phase-II | Discontinued | CD19 | 2014 | no | no | no |
denosumab | Whole mAb | Approved | Active | TNFSF11 | 2005 | no | no | no |
depatuxizumab | Whole mAb ADC | Phase-III | Discontinued | EGFR | 2016 | no | no | no |
depemokimab | Whole mAb | Phase-III | Active | IL5 | 2020 | no | no | no |
derlotuximab | Whole mAb Radiolabelled | Approved | Active | DNA/H1 Complex | 2015 | no | no | no |
dezamizumab | Whole mAb | Phase-II | Discontinued | APCS | 2016 | no | no | no |
dilpacimab | Bispecific mAb | Phase-II | Active | DLL4;VEGFA | 2018 | no;YES | no;no | no;YES |
dinutuximab | Whole mAb | Approved | Active | Ganglioside GD2 | 2013 | no | no | YES |
diridavumab | Whole mAb | Phase-II | Active | Influenza A HA2 | 2014 | YES | no | YES |
disitamab | Whole mAb ADC | Approved | Active | ERBB2 | 2018 | no | no | no |
divozilimab | Whole mAb | Phase-II | Active | MS4A1 | 2020 | no | no | no |
docaravimab | Whole mAb (Mouse) | Approved | Active | Rabies Virus Strain ERA GP Ectodomain Epitope G-III | 2019 | no | no | no |
domagrozumab | Whole mAb | Phase-II | Discontinued | MSTN | 2015 | no | YES | no |
domvanalimab | Whole mAb | Phase-III | Active | TIGIT | 2020 | no | no | no |
donanemab | Whole mAb | Phase-III | Active | APP | 2018 | no | no | no |
dostarlimab | Whole mAb | Approved | Active | PDCD1 | 2018 | no | no | no |
dovanvetmab | Feline Whole mAb | Unknown | Active | IL31 (Feline) | 2019 | no | no | no |
dresbuxelimab | Whole mAb | Phase-I | Active | NT5E | 2021 | no | no | no |
drozitumab | Whole mAb | Phase-II | Discontinued | TNFRSF10B | 2010 | YES | no | no |
duligotuzumab | Whole mAb | Phase-II | Discontinued | ERBB3 | 2012 | no | no | YES |
dupilumab | Whole mAb | Approved | Active | IL4R | 2012 | YES | no | no |
durvalumab | Whole mAb | Approved | Active | CD274 | 2014 | YES | no | no |
dusigitumab | Whole mAb | Phase-II | Discontinued | IGF1&IGF2 | 2012 | no | no | no |
duvortuxizumab | Bispecific scFv with Crossover | Phase-I | Discontinued | CD19;CD3E | 2016 | no;no | no;no | no;no |
ebdarokimab | Whole mAb | Phase-I/II | Active | IL12B | 2020 | no | no | no |
eblasakimab | Whole mAb | Phase-I | Active | IL13RA1 | 2021 | no | no | YES |
ebronucimab | Whole mAb | Phase-II | Active | PCSK9 | 2020 | no | no | no |
ecleralimab | Whole mAb | Phase-II | Active | TSLP | 2021 | no | no | no |
eculizumab | Whole mAb | Approved | Active | C5 | 2002 | YES | no | no |
edrecolomab | Whole mAb | Approved (w) | Discontinued | EPCAM | 1995 | no | no | no |
efalizumab | Whole mAb | Approved | NFD | ITGAL | 2001 | YES | no | no |
efungumab | scFv | Phase-III | Discontinued | Heat Shock Protein 90 Homolog | 2006 | no | no | no |
eldelumab | Whole mAb | Phase-II | Discontinued | CXCL10 | 2013 | no | no | no |
elezanumab | Whole mAb | Phase-II | Active | RGMA | 2016 | no | no | no |
elgemtumab | Whole mAb | Phase-I/II | Discontinued | ERBB3 | 2014 | no | no | YES |
elipovimab | Whole mAb | Phase-I | Active | HIV-1 gp120 | 2018 | no | no | YES |
elotuzumab | Whole mAb | Approved | NFD | SLAMF7 | 2008 | no | no | no |
elranatamab | Bispecific Whole mAb | Phase-II | Active | TNFRSF17;CD3E | 2021 | no;no | no;no | no;no |
eluvixtamab | Bispecific scFv | Phase-I | Active | CD33;CD3E | 2020 | no;no | no;no | no;no |
emactuzumab | Whole mAb | Phase-II | Active | CSF1R | 2014 | YES | no | no |
emapalumab | Whole mAb | Approved | NFD | IFNG | 2016 | no | no | no |
emerfetamab | Bispecific scFv | Phase-I | Active | CD33;CD3E | 2020 | no;no | no;no | no;no |
emibetuzumab | Whole mAb | Phase-II | Active | MET | 2014 | no | no | no |
emicizumab | Bispecific mAb | Approved | NFD | F9;F10 | 2015 | no;no | no;no | no;no |
emirodatamab | Bispecific scFv-scFv-scFc | TBC | Active | FLT3;CD3E | 2022 | no;no | no;no | no;no |
enapotamab | Whole mAb ADC | Phase-II | Discontinued | AXL | 2017 | no | no | no |
enavatuzumab | Whole mAb | Phase-I | Discontinued | TNFRSF12A | 2010 | no | no | no |
encelimab | Whole mAb | Phase-I | Active | LAG3 | 2019 | no | no | no |
enfortumab | Whole mAb ADC | Approved | NFD | PVRL4 | 2013 | no | no | no |
enibarcimab | Whole mAb | Phase-II | Active | ADM | 2020 | no | no | no |
enoblituzumab | Whole mAb | Phase-II | Active | CD276 | 2015 | no | no | no |
enokizumab | Whole mAb | Phase-II | Discontinued | IL9 | 2010 | no | no | no |
enoticumab | Whole mAb | Phase-I | Discontinued | DLL4 | 2012 | no | no | no |
ensituximab | Whole mAb | Phase-II | Active | MUC5AC | 2010 | no | no | no |
ensomafusp | Fusion Protein | Phase-I | Active | CD19 | 2021 | no | no | no |
enuzovimab | Whole mAb | Phase-I | Active | SARS-CoV-2 Spike RBD | 2021 | YES | no | no |
envafolimab | Single Domain Variable Fragment;H | Preregistration | Active | PDL1 | 2018 | no | no | no |
epcoritamab | Bispecific mAb | Phase-III | Active | CD3E;MS4A1 | 2019 | no;no | no;no | no;YES |
epratuzumab | Whole mAb | Phase-III | Discontinued | CD22 | 1999 | no | YES | no |
eptinezumab | Whole mAb | Approved | Active | CALCA&CALCB | 2016 | no | no | no |
eramkafusp | Whole mAb Fusion | Phase-I | Active | CD20 | 2020 | no | YES | no |
erenumab | Whole mAb | Approved | NFD | CALCRL | 2016 | YES | no | no |
erfonrilimab | Bispecific Single Domains (VH-VH'-CH) | Phase-II | Active | CD274;CTLA4 | 2020 | no;YES | no;no | no;no |
etaracizumab | Whole mAb | Phase-II | Discontinued | ITGAV_ITGB3 | 2008 | no | no | no |
etesevimab | Whole mAb | Approved | NFD | SARS-CoV-2 Spike RBD | 2020 | YES | no | no |
etevritamab | Bispecific scFv | Phase-I | Discontinued | EGFR;CD3E | 2020 | no;no | no;no | no;no |
etigilimab | Whole mAb | Phase-I/II | Active | TIGIT | 2017 | no | no | no |
etokimab | Whole mAb | Phase-II | Discontinued | IL13 | 2018 | no | no | no |
etrolizumab | Whole mAb | Phase-III | Active | ITGA4_ITGB7&ITGAE_ITGB7 | 2010 | no | no | no |
evinacumab | Whole mAb | Approved | Active | ANGPTL3 | 2014 | no | no | no |
evolocumab | Whole mAb | Approved | Active | PCSK9 | 2012 | no | no | no |
exidavnemab | Whole mAb | Phase-I | Active | SNCA | 2021 | no | no | no |
ezabenlimab | Whole mAb | Phase-II | Active | PDCD1 | 2019 | no | no | no |
faricimab | Bispecific mAb | Preregistration | Active | VEGFA;ANGPT2 | 2017 | YES;no | no;no | YES;YES |
farletuzumab | Whole mAb | Phase-III | Active | FOLR1 | 2008 | no | no | no |
fasinumab | Whole mAb | Phase-III | Active | NGFB | 2012 | no | no | no |
favezelimab | Whole mAb | Phase-II | Active | LAG3 | 2019 | no | no | no |
fazpilodemab | Bispecific Whole mAb | TBC | Active | KLB;FGFR1 | 2022 | no;no | no;no | no;no |
feladilimab | Whole mAb | Phase-III | Active | ICOS | 2019 | no | no | no |
felzartamab | Whole mAb | Phase-III | Active | CD38 | 2019 | no | no | no |
fepixnebart | Whole mAb | Phase-II | Active | EREG | 2022 | YES | no | no |
fezakinumab | Whole mAb | Phase-I | Discontinued | IL22 | 2009 | no | no | no |
fianlimab | Whole mAb | Phase-I | Active | LAG3 | 2019 | no | no | no |
ficlatuzumab | Whole mAb | Phase-II | Active | HGF | 2011 | no | no | no |
fidasimtamab | Bispecific Whole mAb | Phase-I | Active | PDCD1;ERBB2 | 2021 | no;YES | no;YES | no;YES |
figitumumab | Whole mAb | Phase-I | Discontinued | IGF1R | 2008 | no | no | no |
finotonlimab | Whole mAb | Phase-III | Active | PDCD1 | 2020 | no | no | no |
firivumab | Whole mAb | Preclinical | Discontinued | Influenza A HA | 2014 | no | no | no |
fiztasovimab | Whole mAb | TBC | Active | HHV gB AD-1 | 2022 | no | no | no |
flanvotumab | Whole mAb | Phase-I | Discontinued | TYRP1 | 2011 | no | no | no |
fletikumab | Whole mAb | Phase-II | Discontinued | IL20 | 2013 | no | no | no |
flotetuzumab | Bispecific scFv with Crossover | Phase-I/II | Active | IL3RA;CD3E | 2017 | no;no | no;no | no;no |
fontolizumab | Whole mAb | Phase-II | Discontinued | IFNG | 2002 | no | YES | no |
foralumab | Whole mAb | Phase-II | Active | CD3E | 2010 | no | no | no |
foravirumab | Whole mAb | Phase-II | Discontinued | RV Antigenic Site III | 2008 | no | no | no |
fremanezumab | Whole mAb | Approved | Active | CALCA&CALCB | 2016 | no | no | no |
fresolimumab | Whole mAb | Phase-I | Discontinued | TGFB | 2009 | no | YES | no |
frexalimab | Whole mAb | TBC | Active | CD40LG | 2022 | no | no | no |
frovocimab | Whole mAb | Phase-II | Active | PCSK9 | 2018 | no | no | no |
frunevetmab | Feline Whole mAb | Unknown | Active | NGFB | 2016 | no | no | no |
fulranumab | Whole mAb | Phase-III | Discontinued | NGFB | 2010 | no | YES | no |
futuximab | Whole mAb | Phase-II | Active | EGFR | 2012 | no | no | no |
galcanezumab | Whole mAb | Approved | NFD | CALCA&CALCB | 2015 | no | no | no |
galegenimab | Whole mAb | Phase-II | Active | HTRA1 | 2021 | no | no | no |
galiximab | Whole mAb | Phase-II | Discontinued | CD80 | 2003 | no | no | no |
gancotamab | scFv | Phase-II | Discontinued | ERBB2 | 2018 | no | no | no |
ganitumab | Whole mAb | Phase-III | Active | IGF1R | 2010 | no | no | no |
gantenerumab | Whole mAb | Phase-III | Active | APP | 2012 | YES | no | no |
garadacimab | Whole mAb | Phase-III | Active | F12 | 2018 | no | no | no |
garetosmab | Whole mAb | Phase-II | Active | INHBA | 2018 | no | no | no |
garivulimab | Whole mAb | Phase-I/II | Active | CD274 | 2020 | no | no | no |
gatipotuzumab | Whole mAb | Phase-II | Active | MUC1 | 2016 | no | no | no |
gatralimab | Whole mAb | Phase-I | Discontinued | CD52 | 2019 | YES | no | no |
gedivumab | Whole mAb | Phase-II | Discontinued | Influenza A HA | 2016 | no | no | YES |
gefurulimab | Bispecific Single Domains (VH-VH') | Phase-I | Active | C5;ALB | 2022 | no;no | no;no | no;no |
gemtuzumab | Whole mAb ADC | Approved | NFD | CD33 | 2016 | no | no | no |
geptanolimab | Whole mAb | Preregistration | Active | PDCD1 | 2020 | no | no | no |
gevokizumab | Whole mAb | Phase-III | Active | IL1B | 2010 | YES | no | no |
giloralimab | Whole mAb | Phase-I/II | Active | CD40 | 2019 | no | no | no |
gilvetmab | Canine Whole mAb | Unknown | Active | PDCD1 (Canine) | 2016 | no | no | no |
gimsilumab | Whole mAb | Phase-I | Discontinued | CSF2 | 2017 | no | no | no |
ginisortamab | Whole mAb | Phase-I/II | Active | GREM1 | 2021 | no | no | no |
girentuximab | Whole mAb Radiolabelled | Phase-III | Discontinued | CA9 | 2009 | no | no | no |
glembatumumab | Whole mAb ADC | Phase-III | Discontinued | GPNMB | 2015 | no | no | no |
glenzocimab | Fab | Phase-II | Active | GP6 | 2018 | no | no | no |
glofitamab | Bispecific mAb with Domain Crossover | Phase-III | Active | CD3E;MS4A1 | 2019 | no;YES | no;YES | no;YES |
golimumab | Whole mAb | Approved | Active | TNFA | 2004 | YES | no | no |
golocdacimab | Whole mAb | TBC | Active | OLR1 | 2022 | no | no | no |
gontivimab | Bispecific Single Domains (VH-VH'-VH') | Phase-II | Discontinued | RSV gpF;RSV gpF | 2019 | no;no | no;no | no;no |
gosuranemab | Whole mAb | Phase-II | Discontinued | MAPT | 2018 | no | no | no |
gremubamab | Bispecific mAb | Phase-II | Discontinued | PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas) | 2019 | no;no | no;no | no;no |
gresonitamab | Bispecific scFv-scFv-scFc | Phase-I | Active | CLDN18;CD3E | 2021 | no;no | no;no | no;no |
grisnilimab | Whole mAb | Phase-I/II | Active | CD7 | 2020 | no | no | no |
gumokimab | Whole mAb | Phase-I | Active | IL17A | 2021 | no | no | no |
guselkumab | Whole mAb | Approved | Active | IL23A | 2013 | YES | no | no |
ianalumab | Whole mAb | Phase-II/III | Active | TNFRSF13C | 2017 | no | no | no |
ibalizumab | Whole mAb | Approved | NFD | CD4 | 2007 | YES | no | no |
ibritumomab | Whole mAb | Approved | NFD | MS4A1 | 1999 | YES | no | no |
icrucumab | Whole mAb | Phase-II | Discontinued | FLT1 | 2010 | no | no | no |
idactamab | Whole mAb | Phase-I | Active | SLC1A5 | 2020 | no | no | no |
idarucizumab | Fab | Approved | NFD | Dabigatran | 2013 | YES | no | no |
ieramilimab | Whole mAb | Phase-II | Active | CD223 | 2018 | no | no | no |
ifabotuzumab | Whole mAb | Phase-II | Active | EPHA3 | 2015 | no | no | no |
ifinatamab | Whole mAb | TBC | Active | CD276 | 2022 | no | no | no |
iladatuzumab | Whole mAb ADC | Phase-I | Discontinued | CD79B | 2017 | no | no | no |
imalumab | Whole mAb | Phase-II | Discontinued | MIF | 2014 | YES | no | no |
imaprelimab | Whole mAb | Phase-I | Discontinued | MCAM | 2017 | no | no | no |
imgatuzumab | Whole mAb | Phase-II | Discontinued | EGFR | 2012 | no | no | no |
imsidolimab | Whole mAb | Phase-II | Active | IL36R | 2020 | no | no | no |
imvotamab | Pentameric IgM with Fused scFv | TBC | Active | CD3E;MS4A1 | 2022 | no;no | no;no | no;no |
inclacumab | Whole mAb | Phase-II | Discontinued | SELP | 2011 | no;no | no;no | no;no |
indatuximab | Whole mAb ADC | Phase-II | Discontinued | SDC1 | 2011 | no | no | no |
indusatumab | Whole mAb ADC | Phase-II | Discontinued | GUCY2C | 2014 | no | no | no |
inebilizumab | Whole mAb | Approved | Active | CD19 | 2015 | no | no | no |
inezetamab | Bispecific Mixed mAb and scFv | TBC | Active | CD40;MSLN | 2022 | no;no | no;no | no;no |
infliximab | Whole mAb | Approved | NFD | TNFA | 1997 | YES | no | no |
inotuzumab | Whole mAb ADC | Approved | Active | CD22 | 2004 | no | no | no |
intetumumab | Whole mAb | Phase-II | Discontinued | ITGAV_ITGB3 | 2009 | no | no | no |
iparomlimab | Whole mAb | Phase-I | Active | PDCD1 | 2021 | no | no | no |
ipilimumab | Whole mAb | Approved | Active | CTLA4 | 2005 | YES | no | no |
iratumumab | Whole mAb | Phase-II | Discontinued | TNFRSF8 | 2005 | no | no | no |
isatuximab | Whole mAb | Approved | Active | CD38 | 2014 | YES | no | no |
iscalimab | Whole mAb | Phase-II | Active | CD40 | 2017 | no | no | no |
isecarosmab | Bispecific Single Domains (VH-VH') | Phase-I | Active | ADAMTSL5;ALB | 2019 | no;no | no;no | no;no |
ispectamab | Whole mAb | TBC | Active | TNFRSF17 | 2022 | no | no | no |
istiratumab | Bispecific Mixed mAb and scFv | Phase-II | Discontinued | IGF1R;ERBB3 | 2017 | no;no | no;no | no;no |
itepekimab | Whole mAb | Phase-III | Active | IL33 | 2019 | no | no | no |
itolizumab | Whole mAb | Approved | Active | CD6 | 2010 | no | no | no |
ivicentamab | Bispecific Whole mAb | Phase-I/II | Active | CD37;CD37 | 2021 | no;no | no;no | no;no |
ivonescimab | scFv-IGHC | Phase-II | Active | VEGFA | 2021 | YES | no | YES |
ivuxolimab | Whole mAb | Phase-II | Active | TNFRSF4 | 2019 | no | no | no |
ixekizumab | Whole mAb | Approved | Active | IL17A | 2011 | YES | YES | no |
izalontamab | Bispecific Mixed mAb and scFv | TBC | Active | EGFR;ERBB3 | 2022 | YES;no | YES;no | YES;no |
izenivetmab | Canine Whole mAb | Unknown | Active | NGFB (Canine) | 2022 | no | no | no |
izuralimab | Bispecific Mixed mAb and scFv | Phase-II | Active | ICOS;PDCD1 | 2020 | no;no | no;no | no;no |
labetuzumab | Whole mAb ADC | Phase-II | Discontinued | CEACAM5 | 2015 | no | no | no |
lacnotuzumab | Whole mAb | Phase-II | Active | CSF1 | 2016 | no | no | no |
lacutamab | Whole mAb | Phase-II | Active | KIR3DL2 | 2018 | no | no | no |
ladiratuzumab | Whole mAb ADC | Phase-II | Active | SLC39A6 | 2017 | no | no | no |
lanadelumab | Whole mAb | Approved | NFD | KLKB1 | 2015 | YES | no | no |
landogrozumab | Whole mAb | Phase-II | Discontinued | MSTN | 2015 | no | no | no |
laprituximab | Whole mAb ADC | Phase-I | Discontinued | EGFR | 2015 | no | no | no |
larcaviximab | Whole mAb | Phase-II | Active | Zaire Ebolavirus GP | 2016 | no | YES | no |
latikafusp | Whole mAb Fusion | TBC | Active | PDCD1 | 2022 | no | no | no |
latozinemab | Whole mAb | Phase-III | Active | SORT1 | 2020 | no | no | no |
lebrikizumab | Whole mAb | Phase-III | Active | IL13 | 2009 | YES | no | no |
lecanemab | Whole mAb | Preregistration | Active | APP | 2019 | no | no | no |
lemzoparlimab | Whole mAb | Phase-II | Active | CD47 | 2020 | no | no | no |
lenvervimab | Whole mAb | Phase-III | Active | HBV | 2017 | no | no | no |
lenzilumab | Whole mAb | Preregistration | Active | CSF2 | 2014 | no | no | no |
lepunafusp | Whole mAb Fusion | Phase-I/II | Active | TfR1 | 2021 | no | no | no |
leronlimab | Whole mAb | Phase-III | Active | CCR5 | 2017 | no | no | no |
lesabelimab | Whole mAb | TBC | Active | CD274 | 2022 | no | no | no |
lesofavumab | Whole mAb | Phase-I | Discontinued | Influenza B Virus | 2016 | no | no | no |
letaplimab | Whole mAb | Phase-I/II | Active | CD47 | 2020 | no | no | no |
letolizumab | Single Domain Variable Fragment;H | Phase-I/II | Active | CD40LG | 2016 | no | no | no |
levilimab | Whole mAb | Approved | Active | IL6R | 2018 | no | no | no |
lexatumumab | Whole mAb | Phase-I | Discontinued | TNFRSF10B | 2006 | no | no | YES |
licaminlimab | scFv | Phase-II | Active | TNFA | 2020 | no | no | no |
lifastuzumab | Whole mAb ADC | Phase-II | Discontinued | SLC34A2 | 2013 | no | no | no |
ligelizumab | Whole mAb | Phase-III | Active | IGHE | 2012 | YES | no | no |
ligufalimab | Whole mAb | Phase-I/II | Active | CD47 | 2021 | no | no | no |
lilotomab | Whole mAb ADC | Phase-II | Active | CD37 | 2014 | no | no | no |
lintuzumab | Whole mAb Radiolabelled | Phase-II | Discontinued | CD33 | 1996 | no | no | no |
linvoseltamab | Bispecific Whole mAb | Phase-II | Active | TNFRSF17 | 2022 | no;no | no;no | no;no |
lirentelimab | Whole mAb | Phase-III | Active | SIGLEC8 | 2020 | no | no | no |
lirilumab | Whole mAb | Phase-II | Active | KIRD2 | 2012 | no | no | no |
litifilimab | Whole mAb | Phase-III | Active | CLEC4C | 2022 | no | no | no |
livmoniplimab | Whole mAb | Phase-I | Active | LRRC32 | 2021 | no | no | no |
lodapolimab | Whole mAb | Phase-I | Active | PDL1 | 2019 | no | no | no |
lodelcizumab | Whole mAb | Phase-II | Discontinued | PCSK9 | 2012 | no | no | no |
lokivetmab | Canine Whole mAb | Approved | NFD | IL31 | 2014 | no | no | no |
lomtegovimab | Whole mAb | Phase-I/II | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | no |
loncastuximab | Whole mAb ADC | Approved | Active | CD19 | 2017 | no | YES | no |
lonigutamab | Whole mAb | Phase-I/II | Active | IGF1R | 2020 | no | no | no |
lorigerlimab | Bispecific Mixed scFv (scFv-CH2-CH3-scFv) | Phase-I | Active | PDCD1;CTLA4 | 2021 | no;no | no;no | no;YES |
lorukafusp | Whole mAb Fusion | Phase-II | Active | Ganglioside GD2 | 2018 | no | no | YES |
lorvotuzumab | Whole mAb ADC | Phase-II | Discontinued | NCAM1 | 2010 | no | no | no |
losatuxizumab | Whole mAb ADC | Phase-I | Discontinued | EGFR | 2016 | no | no | no |
lucatumumab | Whole mAb | Phase-I | Discontinued | CD40 | 2007 | no | no | no |
lulizumab | Single Domain Variable Fragment;L | Phase-II | Active | CD28 | 2014 | no | no | no |
lumiliximab | Whole mAb | Phase-II | Discontinued | FCER2 | 2004 | no | YES | no |
lumretuzumab | Whole mAb | Phase-I/II | Discontinued | ERBB3 | 2014 | YES | no | no |
lupartumab | Whole mAb ADC | Phase-I | Active | LYPD3 | 2016 | no | no | no |
lusvertikimab | Whole mAb | Phase-I | Active | IL7R | 2020 | no | no | no |
lutikizumab | Bispecific Dual Variable Domain IG | Phase-II | Discontinued | IL1A;IL1B | 2016 | no;no | no;no | no;no |
luveltamab | Whole mAb ADC | TBC | Active | FOLR1 | 2022 | no | no | no |
maftivimab | Whole mAb | Preregistration | Discontinued | Zaire Ebolavirus GP | 2018 | no | no | no |
magrolimab | Whole mAb | Phase-III | Active | CD47 | 2018 | no | YES | no |
manelimab | Whole mAb | Phase-I | Discontinued | PDL1 | 2019 | no | no | no |
manfidokimab | Whole mAb | Phase-I | Active | IL4R | 2021 | no | no | no |
margetuximab | Whole mAb | Approved | Active | ERBB2 | 2013 | no | no | no |
marstacimab | Whole mAb | Phase-III | Active | ERBB2 | 2013 | no | no | no |
masavibart | Whole mAb | Approved | Active | SARS-CoV-2 Spike RBD | 2020 | YES | no | no |
matuzumab | Whole mAb | Phase-II | Discontinued | EGFR | 2003 | YES | YES | no |
mavrilimumab | Whole mAb | Phase-II/III | Active | CSF2RA | 2009 | no | no | no |
mazorelvimab | Whole mAb | Phase-I/II | Active | Rabies Virus Spike Glycoprotein G | 2021 | no | no | no |
mecbotamab | Whole mAb | Phase-II | Active | AXL | 2022 | no | no | no |
melredableukin | Whole mAb Fusion | Phase-I | Active | Non-Binding | 2021 | no | YES | YES |
melrilimab | Whole mAb | Phase-II | Discontinued | IL1RL1 | 2020 | no | no | no |
mepolizumab | Whole mAb | Approved | Active | IL5 | 1999 | no | no | no |
mezagitamab | Whole mAb | Phase-II | Active | CD38 | 2019 | no | no | no |
mibavademab | Whole mAb | Phase-II | Active | LEPR | 2020 | no | no | no |
milatuzumab | Whole mAb | Phase-I/II | Discontinued | CD74 | 2007 | no | no | no |
mipasetamab | Whole mAb | Phase-I | Active | AXL | 2020 | no | no | no |
miptenalimab | Whole mAb | Phase-II | Active | LAG3 | 2019 | no | no | no |
mirikizumab | Whole mAb | Phase-III | Active | IL23A | 2017 | no | no | no |
miromavimab | Whole mAb (Mouse) | Approved | NFD | Rabies Virus Strain ERA GP Ectodomain Epitope G-II | 2019 | no | no | no |
mirvetuximab | Whole mAb ADC | Phase-III | Active | FOLR1 | 2015 | no | no | no |
mirzotamab | Whole mAb | Phase-I | Discontinued | CD276 | 2019 | no | no | no |
mitazalimab | Whole mAb | Phase-I/II | Active | CD40 | 2017 | no | no | no |
modakafusp | Whole mAb Fusion | Phase-I/II | Active | ADPRC | 2019 | no | no | no |
modotuximab | Whole mAb | Phase-II | Active | EGFR | 2012 | no | no | no |
mogamulizumab | Whole mAb | Approved | Active | CCR4 | 2010 | no | no | no |
monalizumab | Whole mAb | Phase-III | Active | KLRC1 | 2015 | no | no | no |
mosunetuzumab | Bispecific mAb | Phase-III | Active | CD3E;MS4A1 | 2017 | no;no | no;no | no;YES |
motavizumab | Whole mAb | Phase-III | Discontinued | RSV gpF | 2006 | YES | YES | no |
moxetumomab | Fv Fusion | Approved | NFD | CD22 | 2009 | no | no | no |
mupadolimab | Whole mAb | Phase-III | Active | NT5E | 2021 | no | no | no |
murlentamab | Whole mAb | Phase-II | Active | AMHR2 | 2018 | no | no | no |
muromonab | Whole mAb | Approved | Discontinued | CD3E | 1988 | YES | no | no |
nadecnemab | Whole mAb | Phase-II | Active | GFRA3 | 2020 | no | no | no |
nadunolimab | Whole mAb | Phase-II | Active | IL1RAP | 2018 | no | no | no |
namilumab | Whole mAb | Phase-II | Active | CSF2 | 2010 | no | no | no |
naptumomab | Fab Fusion | Phase-III | Discontinued | TPBG | 2006 | no | no | no |
naratuximab | Whole mAb ADC | Phase-II | Active | CD37 | 2015 | no | no | no |
narnatumab | Whole mAb | Phase-I | Discontinued | MST1R | 2011 | no | no | no |
narsoplimab | Whole mAb | Preregistration | Active | MASP2 | 2019 | no | no | no |
natalizumab | Whole mAb | Approved | Active | ITGA4 | 1998 | no | YES | no |
navicixizumab | Bispecific mAb | Phase-I | Active | DLL4;VEGFA | 2015 | no;no | no;no | no;no |
navivumab | Whole mAb | Preclinical | Discontinued | Influenza A HA | 2015 | YES | YES | no |
naxitamab | Whole mAb | Approved | Active | Ganglioside GD2 | 2018 | no | no | no |
necitumumab | Whole mAb | Approved | Active | EGFR | 2008 | YES | no | no |
nemolizumab | Whole mAb | Phase-III | Active | IL31RA | 2014 | no | no | no |
nepuvibart | Whole mAb | Approved | NFD | SARS-CoV-2 Spike RBD | 2020 | YES | no | no |
nesvacumab | Whole mAb | Phase-I | Discontinued | ANGPT2 | 2012 | no | no | no |
netakimab | Whole mAb | Approved | Active | IL17A | 2017 | no | no | no |
nimacimab | Whole mAb | Phase-II | Active | CNR1 | 2018 | no | no | no |
nimotuzumab | Whole mAb | Approved | Active | EGFR | 2005 | no | YES | no |
nipocalimab | Whole mAb | Phase-III | Active | FCGRT | 2019 | no | no | YES |
nirsevimab | Whole mAb | Phase-III | Active | RSV | 2018 | YES | no | YES |
nivatrotamab | Bispecific Mixed mAb and scFv | Phase-I/II | Active | GD2;CD3E | 2020 | no;no | no;no | no;no |
nivolumab | Whole mAb | Approved | Active | PDCD1 | 2012 | YES | no | no |
nofazinlimab | Whole mAb | Phase-III | Active | PDCD1 | 2021 | no | no | no |
nurulimab | Whole mAb | Phase-I | Discontinued | CTLA4 | 2019 | no | YES | no |
obexelimab | Whole mAb | Phase-III | Active | CD19 | 2018 | no | no | no |
obiltoxaximab | Whole mAb | Approved | NFD | Anthrax Protective Antigen | 2015 | no | no | no |
obinutuzumab | Whole mAb | Approved | Active | MS4A1 | 2008 | YES | YES | YES |
obrindatamab | Bispecific scFv with Domain Crossover | Phase-I | Discontinued | CD276;CD3E | 2020 | no;no | no;no | no;no |
ocaratuzumab | Whole mAb | Phase-II | Discontinued | MS4A1 | 2012 | no | no | no |
ociperlimab | Whole mAb | Phase-III | Active | TIGIT | 2020 | no | no | no |
ocrelizumab | Whole mAb | Approved | NFD | MS4A1 | 2005 | no | no | YES |
odesivimab | Whole mAb | Approved | Active | Zaire Ebolavirus GP | 2019 | no | no | no |
odronextamab | Bispecific mAb | Phase-II | Active | MS4A1;CD3E | 2019 | no;no | no;no | no;no |
ofatumumab | Whole mAb | Approved | Active | MS4A1 | 2005 | YES | no | no |
ogalvibart | Whole mAb | TBC | Active | SARS-CoV-2 Spike RBD | 2022 | YES | no | no |
olaratumab | Whole mAb | Approved | Active | PDGFRA | 2010 | no | no | no |
oleclumab | Whole mAb | Phase-II | Active | NT5E | 2016 | no | no | no |
olendalizumab | Whole mAb | Phase-II | Active | C5 | 2015 | no | no | no |
olinvacimab | Whole mAb | Phase-II | Active | KDR | 2018 | no | no | no |
olokizumab | Whole mAb | Phase-III | Active | IL6 | 2010 | YES | no | YES |
omalizumab | Whole mAb | Approved | Active | IGHE | 2000 | YES | YES | YES |
omburtamab | Whole mAb Radiolabelled | Phase-II/III | Active | CD276 | 2018 | YES | no | no |
omodenbamab | Whole mAb | Phase-I/II | Active | SpA | 2020 | no | no | no |
onartuzumab | Fab + di-Fc | Phase-III | Discontinued | MET | 2010 | YES | no | no |
onfekafusp | Whole mAb Fusion | Phase-III | Active | FN extra domain B | 2010 | no | no | no |
ongericimab | Whole mAb | Phase-III | Active | PCSK9 | 2019 | no | no | no |
ontamalimab | Whole mAb | Phase-III | Discontinued | MADCAM1 | 2018 | YES | no | no |
ontuxizumab | Whole mAb | Phase-II | Active | CD248 | 2013 | no | no | no |
onvatilimab | Whole mAb | Phase-I | Active | VSIR | 2017 | no | no | no |
opicinumab | Whole mAb | Phase-II | Discontinued | LINGO1 | 2015 | YES | no | no |
oportuzumab | scFv | Preregistration | Active | EPCAM | 2008 | no | no | no |
opucolimab | Whole mAb | Phase-I | Discontinued | PDL1 | 2019 | no | no | no |
ordesekimab | Whole mAb | Phase-I/II | Active | IL15 | 2020 | no | no | no |
orilanolimab | Whole mAb | Phase-II | Active | FCGRT | 2018 | YES | no | no |
ormutivimab | Whole mAb | Phase-II | Active | Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1 | 2021 | no | no | no |
orticumab | Whole mAb | Phase-II | Active | OxLDL | 2012 | no | no | no |
osemitamab | Whole mAb | TBC | Active | CLDN18 | 2022 | no | no | no |
osocimab | Whole mAb | Phase-II | Active | F11 | 2018 | no | YES | no |
otelixizumab | Whole mAb | Phase-II | Active | CD3E | 2007 | no | no | no |
otilimab | Whole mAb | Phase-III | Active | CSF2 | 2018 | no | YES | YES |
otlertuzumab | di-scFv+Fc | Phase-II | Discontinued | CD37 | 2013 | no | no | no |
oxelumab | Whole mAb | Phase-II | Discontinued | TNFSF4 | 2010 | no | no | no |
ozanezumab | Whole mAb | Phase-II | Discontinued | RTN4 | 2012 | no | no | no |
ozoralizumab | Bispecific Single Domains (VH-VH'-VH) | Preregistration | Active | TNFA;ALB | 2011 | no;no | no;no | YES;no |
ozuriftamab | Whole mAb | Phase-II | Active | ROR2 | 2022 | no | no | no |
pabinafusp | Whole mAb Fusion | Approved | Active | TFRC | 2018 | no | no | no |
pacanalotamab | Bispecific scFv | Phase-I | Active | TNFRSF17;CD3E | 2020 | no;no | no;no | no;no |
pacmilimab | Whole mAb | Phase-II | Active | PDL1 | 2019 | no | no | no |
palivizumab | Whole mAb | Approved | NFD | RSV gpF | 1998 | no | YES | no |
pamrevlumab | Whole mAb | Phase-III | Active | CTGF | 2015 | no | no | no |
panitumumab | Whole mAb | Approved | Active | EGFR | 2004 | YES | no | no |
panobacumab | Whole mAb | Phase-II | Active | Serotype IATS O11 | 2008 | no | no | no |
paridiprubart | Whole mAb | TBC | Active | TLR4 | 2022 | YES | no | YES |
parsatuzumab | Whole mAb | Phase-II | Discontinued | EGFL7 | 2012 | no | no | no |
pasotuxizumab | Bispecific scFv | Phase-I | Discontinued | FOLH1;CD3E | 2014 | no;no | no;no | no;no |
pateclizumab | Whole mAb | Phase-II | Discontinued | LTA | 2011 | YES | no | no |
patritumab | Whole mAb | Phase-III | Active | ERBB3 | 2011 | no | no | no |
pavurutamab | Bispecific scFv | Phase-I | Active | TNFRSF17;CD3E | 2020 | no;no | no;no | no;no |
pelgifatamab | Whole mAb ADC | Phase-I | Active | FOLH1 | 2020 | no | no | no |
pembrolizumab | Whole mAb | Approved | Active | PDCD1 | 2013 | YES | no | no |
penpulimab | Whole mAb | Approved | Active | PDCD1 | 2020 | no | no | no |
pepinemab | Whole mAb | Phase-II | Active | SEMA4D | 2018 | no | no | no |
perakizumab | Whole mAb | Phase-I | Discontinued | IL17A | 2012 | no | no | no |
peresolimab | Whole mAb | Phase-II | Active | PDCD1 | 2022 | no | no | no |
pertuzumab | Whole mAb | Approved | Active | ERBB2 | 2003 | YES | no | YES |
petosemtamab | Bispecific mAb | Phase-I | Discontinued | EGFR;LGR5 | 2019 | no;no | no;no | no;no |
pidilizumab | Whole mAb | Phase-II | Active | PDCD1 | 2012 | no | no | no |
pimivalimab | Whole mAb | Phase-II | Active | PDCD1 | 2020 | no | no | no |
pimurutamab | Whole mAb | Phase-I/II | Active | EGFR | 2019 | no | no | no |
pinatuzumab | Whole mAb ADC | Phase-II | Discontinued | CD22 | 2012 | no | YES | no |
pivekimab | Whole mAb | Phase-I/II | Active | IL3RA | 2021 | no | no | no |
placulumab | Single Domain Variable Fragment (VL) + Fc | Phase-II | Discontinued | TNFA | 2012 | no | no | no |
plamotamab | Bispecific Mixed mAb and scFv | Phase-I | Active | MS4A1;CD3E | 2018 | no;no | no;no | no;no |
plonmarlimab | Whole mAb | Phase-II/III | Active | CSF2 | 2020 | no | no | no |
plozalizumab | Whole mAb | Phase-II | Active | CCR2 | 2015 | no | no | no |
plutavimab | Whole mAb | TBC | Active | SARS-CoV-2 Spike RBD | 2022 | no | no | no |
polatuzumab | Whole mAb ADC | Approved | Active | CD79B | 2012 | no | no | no |
ponezumab | Whole mAb | Phase-II | Discontinued | APP | 2010 | YES | no | no |
ponsegromab | Whole mAb | Phase-I | Discontinued | GDF15 | 2020 | no | no | no |
porgaviximab | Whole mAb | Phase-II | Discontinued | Zaire Ebolavirus GP | 2016 | no | YES | no |
posdinemab | Whole mAb | TBC | Active | MAPT | 2022 | no | no | no |
praluzatamab | Whole mAb | Phase-II | Active | CD166 | 2019 | no | no | no |
prasinezumab | Whole mAb | Phase-II | Active | SNCA | 2017 | no | no | no |
prezalumab | Whole mAb | Phase-II | Discontinued | ICOSLG | 2015 | YES | no | no |
pritoxaximab | Whole mAb | Phase-II | Discontinued | Shiga Toxin Type 1 | 2012 | no | no | no |
prolgolimab | Whole mAb | Phase-III | Active | PDCD1 | 2018 | no | no | no |
pucotenlimab | Whole mAb | Phase-II | Active | PDCD1 | 2020 | no | no | no |
pulocimab | Whole mAb | Phase-I/II | Active | VEGFR2 | 2021 | no | YES | no |
quavonlimab | Whole mAb | Phase-II | Active | CTLA4 | 2019 | no | no | no |
quetmolimab | Whole mAb | Phase-II | Active | CX3CL1 | 2018 | no | no | no |
quilizumab | Whole mAb | Phase-II | Discontinued | IGHE | 2011 | YES | no | no |
quisovalimab | Whole mAb | Phase-II | Active | TNFSF14 | 2021 | no | no | no |
racotumomab | Whole mAb | Approved | Active | Idiotope of anti-NeuGc-ganliosides | 2008 | no | no | no |
radretumab | di-scFv + CH4 | Phase-II | Discontinued | FN extra domain B | 2010 | no | no | no |
rafivirumab | Whole mAb | Phase-II | Discontinued | RV Antigenic Site III | 2008 | no | no | no |
ragifilimab | Whole mAb | Phase-II | Active | TNFRSF18 | 2019 | no | no | no |
ralpancizumab | Whole mAb | Phase-I | Discontinued | PCSK9 | 2013 | no | no | YES |
ramucirumab | Whole mAb | Approved | Active | KDR | 2008 | YES | no | no |
ranevetmab | Canine Whole mAb | Unknown | Active | NGFB | 2016 | no | no | no |
ranibizumab | Fab | Approved | Active | VEGFA | 2004 | YES | no | YES |
ravagalimab | Whole mAb | Phase-II | Active | CD40 | 2017 | YES | no | YES |
ravulizumab | Whole mAb | Approved | Active | C5 | 2017 | no | YES | no |
recaticimab | Whole mAb | Phase-I | Active | PCSK9 | 2020 | no | no | no |
refanezumab | Whole mAb | Phase-II | Discontinued | MAG | 2015 | no | no | no |
regdanvimab | Whole mAb | Approved | Active | SARS-CoV-2 Spike RBD | 2020 | YES | no | no |
relatlimab | Whole mAb | Phase-II/III | Active | LAG3 | 2018 | no | no | no |
relfovetmab | Feline Whole mAb | Unknown | Active | NGFB | 2018 | no | no | no |
remtolumab | Bispecific Dual Variable Domain IG | Phase-II | Discontinued | IL17A;TNFA | 2016 | YES;no | YES;no | no;no |
reozalimab | Bispecific Whole mAb | TBC | Active | PDCD1;CD274 | 2022 | no;no | no;no | no;no |
reslizumab | Whole mAb | Approved | Active | IL5 | 2001 | no | no | no |
retifanlimab | Whole mAb | Preregistration | Active | PDCD1 | 2019 | no | no | no |
retlirafusp | Whole mAb Fusion | Phase-I/II | Active | CD274 | 2020 | no | no | no |
revdofilimab | Whole mAb | Phase-II | Active | TNFRSF4 | 2019 | no | no | no |
rilotumumab | Whole mAb | Phase-II | Discontinued | HGF | 2009 | no | no | no |
rimteravimab | Mixed Nanobody (VHH-CH2-CH3 dimer) | Phase-I/II | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | no |
rinucumab | Whole mAb | Phase-II | Discontinued | PDGFRB | 2015 | no | no | no |
ripertamab | Whole mAb | Phase-III | Active | MS4A1 | 2019 | YES | YES | no |
risankizumab | Whole mAb | Approved | Active | IL23A | 2015 | no | no | no |
rituximab | Whole mAb | Approved | Active | MS4A1 | 1997 | YES | YES | no |
rivabazumab | Fab | Phase-II | Discontinued | PcrV type III secretion system | 2015 | no | no | no |
robatumumab | Whole mAb | Phase-II | Discontinued | IGF1R | 2008 | no | no | no |
rocatinlimab | Whole mAb | Phase-II | Active | TNFRSF4 | 2021 | no | no | no |
roledumab | Whole mAb | Phase-II/III | Active | RHD | 2010 | no | no | no |
rolinsatamab | Whole mAb ADC | Phase-I | Active | PRLR | 2018 | no | no | no |
romilkimab | Bispecific Dual Variable Domain IG | Phase-II | Discontinued | IL13;IL4 | 2017 | no;no | no;no | no;no |
romlusevimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | no |
romosozumab | Whole mAb | Approved | NFD | SOST | 2011 | no | no | no |
rontalizumab | Whole mAb | Phase-II | Discontinued | IFNA1 | 2009 | YES | no | no |
rosmantuzumab | Whole mAb | Phase-I | Discontinued | RSPO3 | 2016 | no | no | no |
rosnilimab | Whole mAb | Phase-II | Active | PDCD1 | 2022 | no | no | no |
rosopatamab | Whole mAb | Phase-III | Active | FOLH1 | 2019 | no | no | no |
rovalpituzumab | Whole mAb ADC | Phase-III | Discontinued | DLL3 | 2015 | no | no | no |
rozanolixizumab | Whole mAb | Phase-III | Active | FCGRT | 2016 | YES | no | no |
rozibafusp | Whole mAb Fusion | Phase-II | Active | ICOS | 2018 | YES | no | no |
rulonilimab | Whole mAb | Phase-I | Active | PDCD1 | 2021 | no | no | no |
runimotamab | Bispecific mAb | Phase-I | Active | ERBB2;CD3E | 2020 | YES;no | YES;no | YES;no |
ruplizumab | Whole mAb | Phase-II | Discontinued | CD40LG | 2000 | YES | no | no |
sabatolimab | Whole mAb | Phase-III | Active | HAVCR2 | 2019 | no | no | no |
sacituzumab | Whole mAb ADC | Approved | Active | TACSTD2 | 2016 | no | no | no |
samalizumab | Whole mAb | Phase-I | Discontinued | CD200 | 2010 | no | no | no |
samrotamab | Whole mAb ADC | Phase-III | Active | LRRC15 | 2017 | no | no | no |
sarilumab | Whole mAb | Approved | Active | IL6R | 2011 | no | no | no |
sasanlimab | Whole mAb | Phase-III | Active | PDCD1 | 2019 | YES | no | no |
satralizumab | Whole mAb | Approved | NFD | IL6R | 2015 | no | no | no |
secukinumab | Whole mAb | Approved | Active | IL17A | 2009 | YES | no | no |
selicrelumab | Whole mAb | Phase-I | Discontinued | CD40 | 2016 | no | no | no |
semorinemab | Whole mAb | Phase-II | Active | MAPT | 2018 | no | no | no |
semzuvolimab | Whole mAb | TBC | Active | CD4 | 2022 | no | no | no |
serclutamab | Whole mAb ADC | Phase-I | Discontinued | EGFR | 2016 | no | no | no |
seribantumab | Whole mAb | Phase-II | Discontinued | ERBB3 | 2012 | no | no | no |
serplulimab | Whole mAb | Preregistration | Active | PDCD1 | 2019 | YES | no | no |
setoxaximab | Whole mAb | Phase-II | Discontinued | Shiga Toxin Type 2 | 2012 | no | no | no |
setrusumab | Whole mAb | Phase-II | Active | SOST | 2017 | no | no | no |
sibeprenlimab | Whole mAb | Phase-I | Active | TNFSF13 | 2020 | no | no | no |
sifalimumab | Whole mAb | Phase-II | Discontinued | IFNA1 | 2009 | YES | no | no |
siltuximab | Whole mAb | Approved | Active | IL6 | 2008 | no | no | no |
simlukafusp | Whole mAb Fusion | Phase-II | Active | FAP | 2019 | no | no | no |
simridarlimab | Bispecific Mixed mAb/VH-VH-CH2-CH3 | Phase-II | Active | CD47;CD274 | 2021 | no;no | no;no | no;no |
simtuzumab | Whole mAb | Phase-II | Discontinued | LOXL2 | 2012 | no | no | no |
sintilimab | Whole mAb | Approved | Active | PDCD1 | 2018 | no | no | no |
sirexatamab | Whole mAb | Phase-II | Active | DKK1 | 2021 | no | no | no |
sirtratumab | Whole mAb ADC | Phase-I | Active | SLITRK6 | 2017 | no | no | no |
sirukumab | Whole mAb | Phase-III | Active | IL6 | 2011 | no | no | no |
socazolimab | Whole mAb | Phase-III | Active | CD274 | 2021 | no | no | no |
sofituzumab | Whole mAb ADC | Phase-I | Discontinued | MUC16 | 2013 | no | no | no |
solanezumab | Whole mAb | Phase-III | Active | APP | 2008 | no | YES | no |
solitomab | Bispecific scFv | Phase-I | Discontinued | EPCAM;CD3E | 2011 | no;no | no;no | no;no |
sotevtamab | Whole mAb | Phase-I | Active | CLU | 2021 | no | no | no |
sotigalimab | Whole mAb | Phase-II | Active | CD40 | 2020 | no | no | no |
sotrovimab | Whole mAb | Approved | Active | SARS-CoV-2 Spike RBD | 2020 | no | YES | YES |
spartalizumab | Whole mAb | Phase-II | Active | PDCD1 | 2017 | no | no | no |
spesolimab | Whole mAb | Phase-III | Active | IL36RN | 2018 | YES | no | no |
suciraslimab | Whole mAb | TBC | Active | CD22 | 2021 | no | no | no |
sudubrilimab | Whole mAb | Unknown | Active | CD274 | 2020 | no | no | YES |
sugemalimab | Whole mAb | Preregistration | Active | PDL1 | 2019 | no | no | no |
suptavumab | Whole mAb | Phase-III | Discontinued | RSV gpF | 2016 | no | no | no |
surzebiclimab | Whole mAb | Phase-I/II | Active | HAVCR2 | 2020 | no | no | no |
sutimlimab | Whole mAb | Preregistration | Active | C1S | 2017 | no | no | no |
suvizumab | Whole mAb | Phase-I | Discontinued | HIV-1 gp120 | 2009 | YES | no | no |
suvratoxumab | Whole mAb | Phase-II | Active | Toxin A | 2016 | YES | no | no |
tabalumab | Whole mAb | Phase-III | Discontinued | TNFSF13B | 2011 | no | no | no |
tabituximab | Whole mAb ADC | Phase-I | Discontinued | FZD10 | 2018 | no | no | no |
tadocizumab | Fab | Phase-II | Discontinued | ITGA2B_ITGB3 | 2005 | no | no | no |
tafasitamab | Whole mAb | Approved | Active | CD19 | 2018 | no | no | no |
tafolecimab | Whole mAb | Phase-III | Active | PCSK9 | 2019 | no | no | no |
tagitanlimab | Whole mAb | Phase-II | Active | CD274 | 2021 | no | no | no |
talacotuzumab | Whole mAb | Phase-III | Active | IL3RA | 2017 | YES | no | no |
talquetamab | Bispecific mAb | Phase-II | Active | GPRC5D;CD3E | 2019 | no;no | no;no | no;no |
tamgiblimab | Whole mAb | Phase-I | Active | TIGIT | 2021 | no | no | no |
tamrintamab | Whole mAb ADC | Phase-I | Active | DPEP3 | 2018 | YES | no | no |
tamtuvetmab | Canine Whole mAb | Unknown | Active | CD52 | 2015 | no | no | YES |
tanezumab | Whole mAb | Preregistration | Active | NGFB | 2008 | YES | no | no |
tarcocimab | Whole mAb | TBC | Active | VEGFA | 2021 | YES | no | YES |
tarextumab | Whole mAb | Phase-II | Active | NOTCH2&3 | 2013 | no | no | no |
tarlatamab | Bispecific scFv | Phase-I | Active | DLL3;CD3E | 2020 | no;no | no;no | no;no |
tavolimab | Whole mAb | Phase-II | Discontinued | TNFSF4 | 2016 | no | no | no |
tebentafusp | scFv Fusion | Preregistration | Active | CD3E | 2017 | no | no | no |
tebotelimab | Bispecific scFv with Crossover | Phase-II/III | Active | PDCD1;LAG3 | 2019 | no;no | no;no | no;no |
tecaginlimab | Bispecific Whole mAb | Phase-I/II | Active | CD40;TNFRSF9 | 2021 | no;no | no;no | no;no |
teclistamab | Bispecific mAb | Phase-II | Active | TNFRSF17;CD3E | 2018 | no;no | no;no | no;no |
telazorlimab | Whole mAb | Phase-II | Active | TNFRSF4 | 2019 | no | no | no |
telisotuzumab | Whole mAb ADC | Phase-I | Discontinued | MET | 2016 | no | no | no |
temelimab | Whole mAb | Phase-II | Active | MRSV envelope protein | 2018 | no | no | no |
tenatumomab | Whole mAb Radiolabelled | Phase-I | Discontinued | TNC | 2007 | no | no | no |
teplizumab | Whole mAb | Preregistration | Active | CD3E | 2007 | no | no | no |
tepoditamab | Bispecific mAb | Phase-I | Discontinued | CLEC12A;CD3E | 2017 | no;no | no;no | no;no |
teprotumumab | Whole mAb | Approved | Active | IGF1R | 2009 | no | no | no |
teropavimab | Whole mAb | Phase-II | Active | HIV-1 gp120 CD4bs | 2021 | no | YES | no |
tesidolumab | Whole mAb | Phase-II | Active | C5 | 2014 | no | no | no |
tesnatilimab | Whole mAb | Phase-II | Active | KLRK1 | 2019 | no | no | no |
tezepelumab | Whole mAb | Preregistration | Active | TSLP | 2015 | YES | no | no |
tibulizumab | Bispecific Mixed mAb and scFv | Phase-I | Discontinued | TNFSF13B;IL17A | 2017 | no;no | no;no | no;YES |
tidutamab | Bispecific Mixed mAb and scFv | Phase-I | Discontinued | SSTR2;CD3E | 2018 | no;no | no;no | no;no |
tifcemalimab | Whole mAb | Phase-I/II | Active | BTLA | 2019 | no | no | no |
tigatuzumab | Whole mAb | Phase-II | Discontinued | TNFRSF10B | 2007 | no | no | no |
tilavonemab | Whole mAb | Phase-II | Active | MAPT | 2018 | no | no | no |
tildrakizumab | Whole mAb | Approved | Active | IL23A | 2012 | no | no | no |
tilogotamab | Whole mAb | Phase-I/II | Active | TNFRSF10B | 2019 | no | YES | no |
tilvestamab | Whole mAb | Phase-I | Active | AXL | 2019 | no | no | no |
timigutuzumab | Whole mAb | Phase-I | NFD | ERBB2 | 1997 | YES | YES | YES |
timolumab | Whole mAb | Phase-II | Discontinued | AOC3 | 2015 | no | no | no |
tinurilimab | Whole mAb | Phase-I | Discontinued | CEACAM6 | 2019 | no | no | no |
tiragolumab | Whole mAb | Phase-III | Active | TIGIT | 2017 | no | no | no |
tirnovetmab | Whole mAb (Canine) | Unknown | Active | IL31 (Canine) | 2020 | no | no | no |
tislelizumab | Whole mAb | Approved | Active | PDCD1 | 2017 | YES | no | no |
tisotumab | Whole mAb | Preregistration | Active | F3 | 2015 | no | no | no |
tixagevimab | Whole mAb | Phase-III | Active | SARS-CoV-2 Spike RBD | 2020 | YES | YES | YES |
tocilizumab | Whole mAb | Approved | Active | IL6R | 2004 | no | no | no |
tomaralimab | Whole mAb | Phase-II | Active | TLR2 | 2018 | no | no | no |
tomuzotuximab | Whole mAb | Phase-II | Active | EGFR | 2016 | no | YES | YES |
toripalimab | Whole mAb | Approved | Active | PDCD1 | 2018 | YES | no | no |
torudokimab | Whole mAb | Phase-II | Active | IL33 | 2020 | no | no | no |
tosatoxumab | Whole mAb | Phase-III | Active | Toxin A | 2013 | no | no | no |
tovetumab | Whole mAb | Phase-II | Discontinued | PDGFRA | 2013 | no | no | no |
tozorakimab | Whole mAb | Phase-II | Active | IL33 | 2020 | no | no | no |
tralokinumab | Whole mAb | Approved | Active | IL13 | 2009 | YES | no | no |
trastuzumab | Whole mAb | Approved | NFD | ERBB2 | 1997 | YES | YES | YES |
tregalizumab | Whole mAb | Phase-II | Discontinued | CD4 | 2010 | no | no | no |
tremelimumab | Whole mAb | Phase-III | Active | CTLA4 | 2005 | YES | no | no |
trevogrumab | Whole mAb | Phase-II | Active | MSTN | 2015 | no | no | no |
trinbelimab | Whole mAb | TBC | Active | RhD | 2021 | no | no | no |
trontinemab | Bispecific Mixed Format with Domain Crossover | TBC | Active | APP Abeta 1-40/42;TFRC | 2022 | YES;no | no;no | no;no |
tusamitamab | Whole mAb | Phase-III | Active | CEACAM5 | 2020 | no | no | no |
tuvonralimab | Whole mAb | Phase-I | Active | CTLA4 | 2021 | no | no | no |
ubamatamab | Bispecific Whole mAb | Phase-I/II | Active | MUC16;CD3E | 2021 | no;no | no;no | no;no |
ublituximab | Whole mAb | Preregistration | Active | MS4A1 | 2010 | no | no | no |
ulenistamab | Whole mAb | Preclinical | Active | PAUF | 2021 | no | no | no |
uliledlimab | Whole mAb | Phase-I/II | Active | NT5E | 2020 | no | no | no |
ulocuplumab | Whole mAb | Phase-I/II | Active | CXCR4 | 2013 | no | no | no |
unasnemab | Whole mAb | Phase-I | Active | RGMA | 2020 | no | no | no |
upanovimab | Whole mAb | Phase-I/II | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | YES |
upifitamab | Whole mAb | Phase-I/II | Active | SLC34A2 | 2019 | no | no | no |
urabrelimab | Whole mAb | Phase-I | Discontinued | CD47 | 2019 | no | no | no |
urelumab | Whole mAb | Phase-II | Active | TNFRSF9 | 2010 | YES | no | no |
ustekinumab | Whole mAb | Approved | Active | IL12B | 2008 | YES | no | no |
utomilumab | Whole mAb | Phase-II | Active | TNFRSF9 | 2016 | YES | no | no |
vadastuximab | Whole mAb ADC | Phase-III | Discontinued | CD33 | 2015 | no | no | no |
valanafusp | Whole mAb Fusion | Phase-II | Active | INSR | 2017 | no | YES | YES |
vandortuzumab | Whole mAb ADC | Phase-I | Discontinued | STEAP1 | 2014 | no | no | no |
vantictumab | Whole mAb | Phase-I | Discontinued | FZD Family | 2013 | no | no | no |
vanucizumab | Bispecific mAb | Phase-II | Discontinued | ANGPT2;VEGFA | 2014 | YES;YES | no;no | no;YES |
varisacumab | Whole mAb | Phase-II/III | Active | VEGFA | 2016 | no | no | no |
varlilumab | Whole mAb | Phase-II | Active | CD27 | 2014 | no | no | no |
vatelizumab | Whole mAb | Phase-II/III | Discontinued | ITGA2 | 2011 | no | no | no |
vedolizumab | Whole mAb | Approved | Active | ITGA4_ITGB7 | 2008 | no | no | no |
veltuzumab | Whole mAb | Phase-II | Discontinued | MS4A1 | 2007 | no | no | no |
vepsitamab | Bispecific scFv-scFv-scFc | Phase-I | Active | MUC17;CD3E | 2021 | no;no | no;no | no;no |
vesencumab | Whole mAb | Phase-I | Discontinued | NRP1 | 2010 | YES | no | no |
vibecotamab | Bispecific Mixed mAb and scFv | Phase-I | Active | IL3RA;CD3E | 2018 | no;no | no;no | no;no |
vibostolimab | Whole mAb | Phase-III | Active | TIGIT | 2019 | no | no | no |
vilamakitug | Whole mAb | TBC | Active | IL1A | 2022 | no | no | no |
vilobelimab | Whole mAb | Phase-III | Active | C5 | 2019 | no | no | no |
visilizumab | Whole mAb | Phase-III | Discontinued | CD3E | 2000 | no | no | no |
visugromab | Whole mAb | TBC | Active | GDF15 | 2022 | no | no | no |
vixarelimab | Whole mAb | Phase-II | Active | OSMR | 2020 | no | no | no |
vixtimotamab | Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody) | Phase-I | Active | CD3E;CD33 | 2020 | no;no | no;no | no;no |
vobarilizumab | Bispecific Single Domains (VH-VH') | Phase-II | Discontinued | IL6R;ALB | 2015 | no;no | no;no | no;no |
vobramitamab | Whole mAb | TBC | Active | CD276 | 2022 | no | no | no |
vofatamab | Whole mAb | Phase-I/II | Active | FGFR3 | 2018 | no | no | YES |
volagidemab | Whole mAb | Phase-II | Active | GCCR | 2018 | no | YES | no |
volrustomig | Bispecific mAb | TBC | Active | CTLA4;PDCD1 | 2022 | YES;no | no;no | no;no |
vonlerolizumab | Whole mAb | Phase-II | Discontinued | TNFRSF4 | 2015 | YES | no | no |
vopratelimab | Whole mAb | Phase-II | Active | ICOS | 2017 | no | no | no |
vorsetuzumab | Whole mAb ADC | Phase-II | Discontinued | CD70 | 2012 | no | no | no |
voxalatamab | Bispecific Whole mAb | Phase-I | Active | FOLH1;CD3E | 2021 | no;no | no;no | no;no |
vudalimab | Bispecific Mixed mAb and scFv | Phase-II | Active | CTLA4;PDCD1 | 2020 | no;no | no;no | YES;no |
vulinacimab | Whole mAb | Phase-I | Active | VEGFR2 | 2019 | no | no | no |
vunakizumab | Whole mAb | Phase-II | Active | IL17A | 2016 | no | no | no |
xeligekimab | Whole mAb | Phase-I | Active | IL17A | 2021 | no | no | no |
xentuzumab | Whole mAb | Phase-II | Active | IGF1&IGF2 | 2015 | no | no | no |
zagotenemab | Whole mAb | Phase-II | Active | MAPT | 2019 | no | no | no |
zalifrelimab | Whole mAb | Phase-II | Active | CTLA4 | 2018 | no | no | no |
zalutumumab | Whole mAb | Phase-II | Discontinued | EGFR | 2005 | no | no | no |
zamerovimab | Whole mAb | Phase-I/II | Active | Rabies Virus Spike Glycoprotein G | 2021 | no | no | no |
zampilimab | Whole mAb | Phase-I/II | Active | TGM2 | 2018 | no | no | no |
zanidatamab | Bispecific mAb | Phase-III | Active | ERBB2;ERBB2 | 2019 | no;YES | no;YES | YES;YES |
zanolimumab | Whole mAb | Phase-III | Discontinued | CD4 | 2004 | no | no | no |
zansecimab | Whole mAb | Phase-II | Active | ANGPT2 | 2020 | no | no | no |
zelminemab | Whole mAb | Phase-II | Active | ADCYAP1R1 | 2019 | no | no | no |
zeluvalimab | Whole mAb | Phase-I | Active | PDCD1 | 2020 | no | no | no |
zenocutuzumab | Bispecific mAb | Phase-II | Active | ERBB3;ERBB2 | 2017 | YES;YES | no;no | no;no |
zilovertamab | Whole mAb | Phase-I/II | Active | ROR1 | 2020 | no | no | no |
ziltivekimab | Whole mAb | Phase-III | Active | IL6 | 2019 | no | no | no |
zimberelimab | Whole mAb | Approved | Active | PDCD1 | 2020 | no | no | no |
zinlirvimab | Whole mAb | TBC | Active | HIV-1 gp120 V3 | 2022 | YES | YES | YES |
zolbetuximab | Whole mAb | Phase-III | Active | CLDN18 | 2017 | no | no | no |
zuberitamab | Whole mAb | Phase-II | Discontinued | MS4A1 | 2019 | no | no | YES |
Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.
Download a spreadsheet of all therapeutic sequences/structures (last list(s) - PL126): xlsx / csv
If you find we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]